Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

"Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"